CCT - Crypto Currency Tracker logo CCT - Crypto Currency Tracker logo
CoinDesk 2025-10-02 14:03:26

Crypto Market Maker GSR to Acquire FINRA-Registered Broker-Dealer Equilibrium Capital Services

Cryptocurrency market maker GSR has signed an agreement to acquire Equilibrium Capital Services, a Portland-based broker-dealer registered with the SEC and a member of FINRA. The deal, which is still pending regulatory approval, marks a step toward expanding GSR’s regulated presence in the United States. GSR did not disclose the terms of the Equilibrium Capital deal in its press release. Equilibrium Capital’s registration allows it to provide brokerage services under U.S. securities laws. By bringing it under its umbrella, GSR expects to offer institutional clients a more direct route into digital assets while operating within established compliance frameworks. GSR executives framed the move as part of a longer-term strategy to deepen its institutional ties in the U.S. Xin Song, the firm’s CEO, said the acquisition reflects GSR’s commitment to serving both entrepreneurs and large investors who want regulated access to crypto markets. The acquisition comes as regulators continue to shape the rules governing digital assets in the U.S. For a firm like GSR — best known for its global market-making and liquidity services — having a broker-dealer license could open doors to products that fall under securities oversight. To manage the acquisition process, GSR engaged Compliance Exchange Group (CXG) for regulatory guidance and BrokerDealerForSale.com for the acquisition of Equilibrium Capital Services. GSR has been steadily building its regulated services portfolio. In recent months, the firm has expanded institutional access to tokenized real-world assets through a partnership with DigiFT, according to a press release. The market making firm also invested in Maverix Securities to support the development of regulated structured products, and led digital-asset treasury investment strategies for Nasdaq-listed companies, including MEI Pharma and Upexi.

Read the Disclaimer : All content provided herein our website, hyperlinked sites, associated applications, forums, blogs, social media accounts and other platforms (“Site”) is for your general information only, procured from third party sources. We make no warranties of any kind in relation to our content, including but not limited to accuracy and updatedness. No part of the content that we provide constitutes financial advice, legal advice or any other form of advice meant for your specific reliance for any purpose. Any use or reliance on our content is solely at your own risk and discretion. You should conduct your own research, review, analyse and verify our content before relying on them. Trading is a highly risky activity that can lead to major losses, please therefore consult your financial advisor before making any decision. No content on our Site is meant to be a solicitation or offer.